title: [Treatment of complicated cavernous venous malformation with retained copper wires combined with pingyangmycin injection].
abstract: OBJECTIVE
  To evaluate the therapeutic effect of retained copper wires combined with pingyangmycin (PYM) injection for complicated cavernous venous malformation.
  
  
  METHODS
  The location of venous malformation was detected by physical examination and MRI. The copper wires in 0.2 mm width were used to puncture the lesion repeatedly and retained in the lesion to form a net. After that, 8 mg PYM was injected into the residue malformed veins. 8-10 days later, the copper wires were taken out and necrotic tissue was squeezed out. The wounds of punctual holes healed through dressing. The patients received postoperative MRI to evaluate the therapeutic effect.
  
  
  RESULTS
  From Jan. 2002 to Dec. 2008, 45 cases were treated. The patients were followed up for 1-3 years. 51.1% (23/45) of the lesions shrinked markedly or even disappeared. 42.2% (19/45) of the lesions reduced. 6.67% (3/45) of the lesions didn't change. There was no complication like invasive infection.
  
  
  CONCLUSIONS
  It is very effective to treat complicated cavernous venous malformation with retained copper wires combined with pingyangmycin injection.
authors.affiliation: Department of Plastic and Burn Surgery, Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing 210002, China.
authors.forename: Si-Ming
authors.initials: SM
authors.lastname: Yuan
authors.forename: Hui-Qing
authors.initials: HQ
authors.lastname: Jiang
authors.forename: Zhi-Jian
authors.initials: ZJ
authors.lastname: Hong
authors.forename: Xiu-Kun
authors.initials: XK
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Xin-Bao
authors.initials: XB
authors.lastname: Hu
mesh_terms: D001165:Arteriovenous Malformations / Q000628:therapy*; D001761:Bleomycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002408:Catheters, Indwelling; D002648:Child; D003300:Copper / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D055815:Young Adult
chemical_list: D001761:Bleomycin; C025703:bleomycetin; D003300:Copper